Paper in Focus

Karim KE, Wu CM, Giladi AM, Murphy MS.
Orthobiologic Therapies in Hand Surgery.
J Hand Surg Am. 2021;46(5):409-415.
doi:10.1016/j.jhsa.2021.01.006
PMID: 33958102

Read the full article:
https://pubmed.ncbi.nlm.nih.gov/33958102/

Opening Editorial: Editor’s Perspective

Few areas in orthopaedics generate as much enthusiasm and controversy as orthobiologics.

From platelet-rich plasma (PRP) to bone marrow aspirate concentrate and mesenchymal stem cell therapies, biologic augmentation has rapidly expanded across subspecialties. In hand surgery, where small structures and precise function define outcomes, the theoretical appeal of biologics is strong.

But theory is not evidence.

This issue of Conversations in Orthopaedics examines a Current Concepts Review in The Journal of Hand Surgery that critically evaluates orthobiologic therapies in upper-extremity conditions. Rather than advocating for adoption, the authors carefully assess the quality of evidence supporting current applications.

Why This Paper Matters

Orthobiologics are frequently marketed as regenerative solutions capable of:

• Accelerating tendon healing

• Enhancing bone union

• Reducing inflammation

• Avoiding surgical intervention

In practice, however, the regulatory environment, variable preparation methods, and inconsistent study designs create substantial heterogeneity in outcomes.

In hand surgery, where surgical precision and predictable outcomes are essential, the threshold for adoption should be high.

This review provides a valuable framework for evaluating that threshold.

Study Overview

This is a narrative Current Concepts Review analyzing available literature on orthobiologic use in hand and wrist pathology.

The authors review evidence across several biologic categories:

• Platelet-rich plasma (PRP)

• Bone marrow aspirate concentrate (BMAC)

• Mesenchymal stem cells

• Bone morphogenetic proteins (BMPs)

• Amniotic-derived products

They evaluate applications in:

• Tendinopathies

• Nerve compression syndromes

• Fracture healing

• Ligament injuries

• Degenerative joint conditions

Importantly, the paper focuses not only on reported outcomes but on study quality and methodological rigor.

Key Findings: What the Evidence Actually Shows

1. Platelet-Rich Plasma (PRP)

PRP is one of the most studied orthobiologic agents, yet results remain inconsistent. Preparation techniques vary widely, and high-level randomized data in hand-specific conditions are limited.

Some studies suggest symptomatic improvement in tendinopathies, but reproducibility remains uncertain.

2. Bone Marrow Aspirate Concentrate (BMAC) and Stem Cell Therapies

The biologic rationale is compelling: mesenchymal stem cells may enhance tissue regeneration.

However, most evidence consists of small case series and early-phase investigations. There is insufficient high-quality comparative data to support routine use in hand pathology.

3. Bone Morphogenetic Proteins (BMPs)

BMPs have established roles in spine and long bone surgery, but their application in hand surgery is more limited. Concerns regarding heterotopic ossification and soft tissue complications warrant caution.

4. Amniotic and Placental Products

These products are increasingly marketed for anti-inflammatory and regenerative properties. However, robust, hand-specific clinical trials are scarce, and regulatory oversight varies.

Strengths of the Review

This paper stands out because it:

• Emphasizes the level of evidence rather than anecdote

• Separates biologic plausibility from clinical validation

• Highlights methodological limitations across studies

• Encourages evidence-based skepticism

It avoids overstating conclusions, a refreshing approach in a field prone to marketing-driven enthusiasm.

Limitations of the Current Evidence

The authors highlight several recurring issues:

• Small sample sizes

• Lack of standardized biologic preparation protocols

• Heterogeneous outcome measures

• Limited long-term follow-up

• Sparse randomized controlled trials

Without standardization and reproducibility, widespread adoption remains premature.

Broader Perspective: The Innovation Paradox

Orthopaedics has always balanced innovation with discipline.

Biologics represent a fascinating paradox:

The science is promising.
The marketing is aggressive.
The evidence remains incomplete.

For surgeons, the responsibility is not to resist innovation but to demand data.

Especially in hand surgery, where small functional deficits can significantly impact patient quality of life, caution is warranted.

Future Directions

The path forward requires:

• Standardized preparation protocols

• High-quality randomized controlled trials

• Clear regulatory frameworks

• Long-term outcome reporting

• Cost-effectiveness analysis

Until then, orthobiologics in hand surgery should be viewed as adjunctive and investigational rather than standard of care.

Closing Perspective

Biologic therapies may ultimately reshape orthopaedic practice.

But enthusiasm must never outpace evidence.

This review reminds us that scientific rigor, not market momentum, should guide clinical adoption.

And in hand surgery, precision must apply not only to technique, but to decision-making.

Discussion Questions

1. Should orthobiologics in hand surgery be restricted to research settings until higher-level evidence is available?

2. How should surgeons counsel patients who request biologic therapies based on marketing claims?

3. What minimum evidence threshold should define “standard of care” in regenerative orthopaedics?
   

   Thanks for reading! Subscribe for free to receive new posts and support my work.